HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Anal cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 21 Apr 2017 to 30 Jun 2017.
- 29 Mar 2017 Planned initiation date changed from 21 Mar 2017 to 21 Apr 2017.